Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …

Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …

Research into the role of the human epidermal receptor growth factor receptor 1/epidermal
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …

In phase I trials in healthy volunteers and patients with refractory cancers, erlotinib (Tarceva)
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …

Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …

Erlotinib (Tarceva), is an orally available, reversible inhibitor of epidermal growth factor
receptor (EGFR; HER1) that exhibits inhibitory activity on purified HER2 kinase at much …

Our objective was the preclinical assessment of the pharmacokinetics, monotherapy and
combined antitumor activity of the epidermal growth factor receptor (HER1/EGFR) tyrosine …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …

Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …

Abstract Purpose: Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. In phase II clinical studies …